Pliant Therapeutics, Inc. (PLRX)

Market Cap	72.45M -30.2%
Revenue (ttm)	n/a
Net Income	-92.29M
EPS	-1.50
Shares Out	61.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,460
Open	1.140
Previous Close	1.130
Day's Range	1.140 - 1.180
52-Week Range	1.020 - 1.950
Beta	1.28
Analysts	Hold
Price Target	2.00 (+70.94%)
Earnings Date	Aug 11, 2026

About PLRX

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Analyst Summary

According to 4 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $2.0, which is an increase of 70.94% from the latest price.

Price Target

$2.0

(70.94% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 12, 2026

Data Sources Report a data error